Naveed Shah, MD
Pulmonary Disease · Finksburg, MDNPI 1477575546
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,002 of the $12,713 with a category attached, or 62.9%. Sunovion Pharmaceuticals Inc. accounts for 70.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $10,567 and has fallen 98.4% since, to $167 in 2025.
Across 209 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$9K
- Mylan Specialty L.p.$1K
- GSK$726
- AstraZeneca$497
- Boehringer Ingelheim$477
- Harmony Biosciences LLC$128
- plus $765 from 19 others
What the payments were for
- Speaking & faculty fees$8,00263%
- Travel & lodging$1,41811%
- Food & beverage$3,29326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 22 | $8,991 |
| Mylan Specialty L.p. | 27 | $1,129 |
| GSK | 57 | $726 |
| AstraZeneca | 24 | $497 |
| Boehringer Ingelheim | 30 | $477 |
| Harmony Biosciences LLC | 7 | $128 |
| Sanofi | 5 | $97 |
| Resmed Corp | 5 | $91 |
| Mallinckrodt Enterprises LLC | 3 | $72 |
| Genentech USA, Inc. | 4 | $72 |
| Circassia Inc. | 4 | $62 |
| Fisher & Paykel Healthcare Inc | 3 | $48 |
| Grifols USA, LLC | 2 | $46 |
| 3b Medical, Inc. | 2 | $41 |
| Advanced Respiratory, Inc | 3 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Stryker | 1 | $27 |
| Baxter Healthcare | 1 | $22 |
| Covidien LP | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
| Insmed, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$8,698
- Yupelri$722
How this compares
$12,713 in reported general payments places this provider in the 80th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Glycopyrrolate | 15 | $510 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Finksburg
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- da Wei LiaoBethesda$310K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.